However, atomic‐resolution structures of full‐length and truncated alpha‐synuclein (1–121) fibrils,45, 46, 60 as well as those obtained from brains published recently47, 48 support the new approach presented in this study for achieving the desired protective immunity against synucleinopathies through the rational design of candidate vaccines based on structure. The gene discussed is SNCA; the disease is synucleinopathy.